Ecovia Bio has secured a Series B funding round to expand manufacturing capacity as demand grows for biodegradable alternatives to petrochemical-based polymers.WHO: Founded in 2014 by a faculty member and a PhD graduate, Ecovia Bio is a biotechnology company—a University of Michigan spinout—focused on developing and commercializing sustainable, high-performance biopolymers derived from fermentation processes. The company's lead technology is based on gamma polyglutamic acid (γ-PGA), a natural biodegradable polymer with applications across multiple industries.WHY: The funding will support the significant expansion of manufacturing capacity at Ecovia Bio's state-of-the-art Livonia, Michigan, facility. Its products are designed to reduce dependence on petrochemicals while delivering superior performance in demanding applications. By expanding manufacturing capacity and establishing a roadmap for additional production sites, Ecovia Bio is positioning itself to become the trusted global supplier of choice for γ-PGA and related biopolymers across consumer and industrial markets.IN THEIR OWN WORDS: "We are excited to partner with Pointe Angels," said Kousay Said, CEO of Ecovia Bio. "This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale.""Ecovia Bio represents exactly the kind of venture we love to back at Pointe Angels," said David Bloom, Executive Director of Pointe Angels.